Abstract Number: 0174 • ACR Convergence 2025
Genetic and Environmental Risk Factors and Incident Rheumatoid Arthritis
Background/Purpose: While some studies have linked air pollution to risk for rheumatoid arthritis (RA), U.S.-based studies utilizing nationwide exposure data remain limited and often exclude…Abstract Number: 0091 • ACR Convergence 2025
Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Rheumatoid Arthritis: associations with treatment response and comorbidities
Background/Purpose: Clonal hematopoiesis (CH) of indeterminate potential (CHIP) is defined as the detection of recurrent somatic mutations, at a variant allele frequency (VAF) < ![if…Abstract Number: 0072 • ACR Convergence 2025
Impact of Baricitinib on Cardiovascular Health in Biologic-naïve Rheumatoid Arthritis patients: A Comparative Study with TNF Inhibitors and Conventional DMARDs
Background/Purpose: Therapeutic advances in RA have introduced effective treatments, including b/tsDMARDs such as Baricitinib. However, its cardiovascular safety profile remains unclear, partly due to the…Abstract Number: 0049 • ACR Convergence 2025
Enhanced Src Homology Region 2 Domain-containing Phosphatase 1 Activity Ameliorates Murine Inflammatory Arthritis Through the Innate Immune System
Background/Purpose: Src homology region 2 domain-containing phosphatase 1 (SHP-1) is a cytoplasmic protein tyrosine phosphatase expressed in hematopoietic cells (PMID9069265). SHP-1 is a key negative…Abstract Number: 2661 • ACR Convergence 2025
Heterogeneity of RA-ILD by Longitudinal Forced Vital Capacity Measurements Is Associated with Survival and Respiratory Hospitalization
Background/Purpose: Forced vital capacity (FVC) is one of the primary disease measures monitored in RA-associated interstitial lung disease (RA-ILD). While prior studies have suggested a…Abstract Number: 2567 • ACR Convergence 2025
Temporal Trends in Cardiometabolic Multimorbidity Risk in Rheumatoid Arthritis: A National, Matched Cohort Study
Background/Purpose: Multimorbidity, the presence of multiple chronic conditions, is over-represented in RA. A cardiometabolic multimorbidity (CMM) phenotype has emerged in the general population, but is…Abstract Number: 2278 • ACR Convergence 2025
Neuroimmune modulation for the Treatment of Rheumatoid Arthritis: Results at 12 months from a Randomized, Sham-Controlled, Double-Blind Study
Background/Purpose: Neuroimmune modulation by electrical stimulation of the left cervical vagus nerve represents a novel treatment option for rheumatoid arthritis (RA). We present 12-month efficacy…Abstract Number: 2263 • ACR Convergence 2025
Comparison of a Patient-Reported Disease Activity Measure with Physician-Based Indices in Rheumatoid Arthritis Patients in Nigeria
Background/Purpose: Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation of synovial joints with extra articular manifestations. Disease activity indices in Rheumatoid…Abstract Number: 2246 • ACR Convergence 2025
Different Populations, Different SDAI Cut-Off? A Proposal for a New Remission Threshold in Brazilian RA Patients from a National Multicenter Study
Background/Purpose: Remission criteria in Rheumatoid Arthritis (RA) have continuously evolved to balance the risks of both overtreatment and undertreatment. The most recent update includes the…Abstract Number: 2229 • ACR Convergence 2025
National Multicenter study of Baricitinib in Rheumatoid Arthritis – Interstitial Lung Disease: effectiveness and progressive lung disease
Background/Purpose: Interstitial lung disease (ILD) in Rheumatoid Arthritis (RA) determines a worse prognosis with an increased mortality. Abatacept and rituximab may be the preferred therapies.…Abstract Number: 1982 • ACR Convergence 2025
Bridging the Gap in Underserved Care: A Quality Improvement Initiative to Increase Pneumococcal Vaccination Rates in Immunocompromised Rheumatology Patients
Background/Purpose: Patients with rheumatologic conditions who are on immunosuppressive therapy face an elevated risk of pneumococcal infections, particularly those in medically underserved populations. Per ACR…Abstract Number: 1896 • ACR Convergence 2025
Electronic Cigarette Use in Association with Risks of Developing Rheumatoid Arthritis or Systemic Lupus Erythematosus in the All of Us Research Program
Background/Purpose: Electronic cigarettes, or e-cigarettes, are inhalable aerosol nicotine-delivery devices increasingly used in addition or in place of cigarettes. Cigarette smoking is strongly associated with…Abstract Number: 1732 • ACR Convergence 2025
Incidence of Flares in Pre-existing Rheumatologic Diseases Among Patients with Solid Tumors Undergoing Cancer Immunotherapy: A Systematic Review and Meta-analysis
Background/Purpose: Immune checkpoint inhibitors (ICIs) have become essential in cancer treatment, offering significant survival benefits across various malignancies. However, ICIs can cause immune-related Adverse Events…Abstract Number: 1658 • ACR Convergence 2025
Cardiovascular Disease Risk and Risk Calculator Performance in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Background/Purpose: Existing cardiovascular disease (CVD) risk stratification strategies underperform in RA. Lung disease is an established CVD risk factor, and RA-interstitial lung disease (RA-ILD) clinically…Abstract Number: 1367 • ACR Convergence 2025
Molecular Signature Response Classifier Identifies Contribution of GLP-1 Therapy to TNF Inhibitor Response in Rheumatoid Arthritis Patients
Background/Purpose: Tumor necrosis factor-α inhibitors (TNFi) are extensively utilized in the management of rheumatoid arthritis (RA). Therapeutic responses remain highly heterogeneous. Emerging evidence suggests glucagon-like…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 219
- Next Page »